Company intelligence / Profile preview

AphaMax

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

AphaMax is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) and multi-specific antibodies for the treatment of cancer. The company utilizes its proprietary site-specific conjugation technology and novel linker-payload platforms to enhance the efficacy and safety profiles of its therapeutic candidates. AphaMax's pipeline features several promising programs targeting solid tumors, including candidates directed at HER2, TROP2, and Claudin 18.2. Based in Suzhou, China, the company is positioned to advance precision oncology through its integrated R&D capabilities and proprietary Apha-ADC platform.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateBispecific monoclonal antibodyMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on AphaMax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AphaMax.

Explore the full profile